PT Novartis Indonesia (Indonesia)

Novartis Indonesia is primarily engaged in medicines, capsuled or ampuled activity. Its headquarters is located in Dki Jakarta. The company was founded in 1985. Novartis Indonesia operates as a subsidiary of Novartis AG, a global healthcare company based in Switzerland. The company focuses on the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Novartis Indonesia's primary business line is pharmaceuticals, with a secondary focus on consumer health products. The company offers a diverse portfolio of products, including innovative prescription medicines and over-the-counter health solutions. Some of the key therapeutic areas include oncology, cardiology, ophthalmology, and neuroscience. Novartis is known for its leading brands such as Gleevec, Diovan, and Lucentis. Novartis Indonesia has a significant presence in the local market, with several branches and distribution networks across major cities in Indonesia. The company is committed to expanding its reach and improving access to healthcare solutions throughout the country. Globally, Novartis operates in over 155 countries, with a strong presence in Europe, North America, and Asia-Pacific. The company collaborates with various international research institutions and healthcare organizations to advance medical research and innovation. Novartis Indonesia is a member of several industry associations, including the Indonesian Pharmaceutical Association, and actively participates in initiatives to improve healthcare standards in the region. The company is dedicated to its mission of discovering new ways to improve and extend people's lives. Novartis aims to lead in innovation and sustainability, with a vision to transform the practice of medicine and enhance patient outcomes worldwide.